Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Wählen Sie die Spezies und Applikation aus
anti-Human EHD2 Antikörper:
anti-Mouse (Murine) EHD2 Antikörper:
anti-Rat (Rattus) EHD2 Antikörper:
Sie gelangen zu unserer vorgefilterten Suche.
Human Polyclonal EHD2 Primary Antibody für ELISA, WB - ABIN547344
Guilherme, Soriano, Furcinitti, Czech: Role of EHD1 and EHBP1 in perinuclear sorting and insulin-regulated GLUT4 recycling in 3T3-L1 adipocytes. in The Journal of biological chemistry 2004
Human Polyclonal EHD2 Primary Antibody für IHC, IHC (p) - ABIN4307515
Kim, Kim, Jeon, Kim, Kim, Bae, Jung: Prognostic implication of histological features associated with EHD2 expression in papillary thyroid carcinoma. in PLoS ONE 2017
EHD2 can promote the proliferation, invasion, and migration and inhibit the apoptosis of clear cell renal cell carcinoma (ccRCC) cells, so EHD2 interference can significantly inhibit the development of ccRCC, and EHD2 can potentially serve as a molecular target for the clinical treatment of ccRCC.
findings therefore define EHD2 as a central player in mechanotransduction connecting the disassembly of the caveolae reservoir with the regulation of gene transcription under mechanical stress.
EHD2 overexpression in human adipocytes increased the lipolytic signaling and suppressed the activity of transcription factor PPARgamma. Overall, these data suggest that EHD2 plays a key role for adipocyte function.
Our prognostic model is useful for predicting persistent/recurrent disease after surgery of Papillary thyroid carcinoma (PTC). EHD2 mRNA expression could be a novel prognostic marker for PTC patients.
EHD2 expression, along with the epithelial marker E-cadherin, was markedly reduced in tumor tissues than in adjacent noncancerous tissues. Molecular data indicated that EHD2 inhibited migration and invasion of hepatocellular carcinoma probably by interacting with E-cadherin.
Data suggest that the EH-domain containing 2 protein (EHD2) NPF phenylalanine residue is crucial for EHD2 localization to the plasma membrane, whereas the proline residue is essential for EHD2 dimerization and binding.
EHD2 can inhibit the metastasis of human breast cancer by regulating the epithelial-to-mesenchymal transition markers E-cadherin and N-cadherin.
Downregulation of EHD2 was associated with migration and invasion by abrogating the expression of Rac1 in breast cancer patients.
Phosphatidylinositol 4,5-bisphosphate controls EHD2 plasma membrane localization.
Our results suggested that EHD2 low expression is involved in the pathogenesis of human esophageal squamous cell carcinoma
EHD2 participates in the sarcolemma repair.
Assembly of EHD2 stabilized and constrained caveolae to the plasma membrane to control turnover, and depletion of EHD2, resulting in endocytic and more dynamic and short-lived caveolae.
Among three EHD proteins (EHD1-EHD3) that were tested, only EHD2 accumulates in the nucleus under nuclear export inhibition treatment.
Confining caveolae to the plasma membrane by EHD2 relied on its capacity to link caveolae to actin filaments.
EHD2 regulates trafficking from the plasma membrane by controlling Rac1 activity.
A new class of cardiac trafficking proteins(EHD1, EHD2, EHD3, EHD4) regulates cardiac membrane protein targeting.
EHD2 may be cardioprotective as a dominant-negative EHD2 mutant sensitized cardiomyocytes to ischemic damage. Our findings highlight EHD2 as a potential pharmacologic target in the treatment of diseases with KATP channel trafficking defects
EHD1, EHD2, and EHD4 are recruited to caveolae. Recruitment of the other EHDs increases markedly when EHD2, which has been previously detected at caveolae, is absent. Construction of knockout cell lines lacking EHDs 1, 2, and 4 confirms this apparent functional redundancy.
The regulatory N-terminal residues and the EH domain keep the EHD2 dimer in an autoinhibited conformation in solution. By significantly advancing the use of infrared reflection-absorption spectroscopy, we demonstrate that EHD2 adopts an open conformation by tilting the helical domains upon membrane binding.
The helical domain of EHD2 is inserted into the membrane.The N terminus domain regulates caveolar targeting of EHD2.
The characterization of Fer1L5 and its interaction with EHD1 and EHD2 underscores the complex requirement of ferlin proteins and mediators of endocytic recycling for membrane trafficking events during myotube formation
appears to connect endocytosis to the actin cytoskeleton through interactions of its N-terminal domain with membranes and its C-terminal EH domain with the novel EHBP1 protein
interaction of myoferlin with EHD2 identifies molecular overlap between the endocytic recycling pathway and the machinery that regulates myoblast membrane fusion
This gene encodes a member of the EH domain-containing protein family. These proteins are characterized by a C-terminal EF-hand domain, a nucleotide-binding consensus site at the N terminus and a bipartite nuclear localization signal. The encoded protein interacts with the actin cytoskeleton through an N-terminal domain and also binds to an EH domain-binding protein through the C-terminal EH domain. This interaction appears to connect clathrin-dependent endocytosis to actin, suggesting that this gene product participates in the endocytic pathway.
EH domain containing 2
, EH domain-containing protein 2
, PAST homolog 2
, putative eps protein
, EH-domain containing 2
, EH-domain containing 1
, EH-domain-containing protein 2
, EH domain-containing protein 2-like